Table 4 Predictors of pulmonary function growth
|  | FEV1% predicted Δ / year | FVC % predicted Δ / year | FEV1/FVC Δ / year |
|---|---|---|---|
Neonatal | |||
GA (1 week) | − 0.0038 (− 0.95, 0.95) | 1 (− 0.28, 2.4) | − 0.14 (− 0.97, 0.69) |
BW (100 g) | 0.22 (− 0.43, 0.87) | − 0.071 (− 0.94, 0.8) | 0.33 (− 0.19, 0.85) |
SGA | − 2.4 (− 7.6, 2.9) | − 1.1 (− 7.5, 5.3) | − 1.2 (− 5.1, 2.7) |
Multiple gestation | − 0.00061 (− 2.7, 2.7) | − 2.5 (− 6.3, 1.3) | 1 (− 1.4, 3.5) |
Antenatal steroids (any) | − 1.6 (− 6, 2.8) | 1.3 (− 8.3, 11) | − 3.2 (− 8.6, 2.2) |
Antenatal steroids (complete) | 1.7 (− 2.6, 5.9) | 1 (− 5.4, 7.4) | 0.45 (− 3, 3.9) |
Surfactant | − 0.77 (− 9.5, 7.9) | 4.8 (− 8.2, 18) | − 5.2 (− 13, 2.5) |
Ventilated days (1 day) | − 0.026 (− 0.045, − 0.0074)* | − 0.011 (− 0.037, 0.014) | − 0.017 (− 0.03, − 0.0047)* |
CPAP days (1 day) | 0.011 (− 0.068, 0.09) | 0.053 (− 0.05, 0.16) | − 0.026 (− 0.09, 0.038) |
PDA | 0.29 (− 3.3, 3.9) | − 3.6 (− 8.8, 1.7) | 0.6 (− 2.5, 3.7) |
PDA ligation | − 0.17 (− 3.1, 2.8) | − 2.1 (− 6.2, 2.1) | 3.2 (1.1, 5.3)* |
NEC | 2.8 (− 0.98, 6.6) | 3.3 (− 1.5, 8.1) | 1.2 (− 1.7, 4.2) |
Severe IVH | − 2.3 (− 9.1, 4.4) | − 2 (− 8.5, 4.5) | − 0.66 (− 6.1, 4.8) |
Postnatal steroids (in NICU) | − 2.8 (− 6, 0.44) | − 3.9 (− 7.3, − 0.38)* | − 1.8 (− 5.2, 1.6) |
Gastrostomy tube | − 3.4 (− 6.5, − 0.3)* | − 1.2 (− 4.9, 2.4) | 0.26 (− 2.4, 2.9) |
Tracheostomy | − 4.5 (− 9.3, 0.36) | − 4.7 (− 11, 1.6) | − 4.8 (− 8.3, − 1.3)* |
Discharge off breast milk | − 0.55 (− 2.3, 1.2) | 1.2 (− 1.3, 3.7) | − 0.19 (− 1.8, 1.4) |
Any resp support at 36 weeks | − 2.1 (− 5.8, 1.5) | 0.59 (− 4.1, 5.2) | − 1.4 (− 4.4, 1.5) |
Any resp support at discharge | − 0.028 (− 2.9, 2.9) | 1.3 (− 2.8, 5.3) | − 2.5 (− 4.9, 0.021) |
Maternal history | |||
Age | 0.16 (− 0.13, 0.45) | 0.017 (− 0.38, 0.41) | − 0.008 (− 0.23, 0.21) |
Asthma | − 3.2 (− 6, − 0.37)* | − 0.75 (− 5, 3.5) | − 2.1 (− 4.6, 0.36) |
Eczema | − 0.13 (− 4.1, 3.8) | 0.49 (− 4.5, 5.5) | 1.9 (− 1.2, 4.9) |
Hay fever | − 0.46 (− 3.9, 3) | − 2.6 (− 7.3, 2) | − 1.4 (− 4.2, 1.3) |
Atopy | − 2.9 (− 5.7, − 0.13)* | − 2.1 (− 6.2, 2.1) | − 0.33 (− 2.8, 2.2) |
Secondhand smoke exposure at home | 1.3 (− 3.7, 6.2) | 0.89 (− 5, 6.8) | 0.57 (− 3, 4.2) |
Follow-up (0–3 year) history (n = 42) | |||
Received palivizumab | − 1.7 (− 13, 9.3) | − 1.3 (− 20, 17) | − 4 (− 15, 6.5) |
Received flu vaccination | − 2.8 (− 12, 6.9) | − 0.74 (− 15, 13) | − 2.8 (− 13, 7) |
Any ED Visit/hospitalization | 2.1 (− 6.4, 11) | − 1.5 (− 16, 13) | 0.76 (− 8.5, 10) |
Any hospitalization | − 11 (− 23, 1.7) | − 5.3 (− 41, 30) | 0.89 (− 12, 14) |
Any lower respiratory tract infection | 5.2 (− 3.5, 14) | − 10 (− 25, 3.8) | 0.74 (− 14, 16) |